| Variable | Result |
| Age years | 54.15±13.50 |
| Sex | |
| Males | 83 (43.5) |
| Females | 108 (56.5) |
| Age when diagnosed years | |
| 0–5 | 16 (8.4) |
| >5 | 175 (91.6) |
| BTS treatment step | |
| 2 | 57 (29.84) |
| 3 | 111 (58.12) |
| 4 | 23 (12.04) |
| Smoking pack-years | 0 (0–4) |
| Height cm | 169.24±9.89 |
| Mass kg | 81.14±17.31 |
| BMI kg·m−2 | 28.27±5.36 |
| BDP-equivalent¶ daily dose μg·day−1 | 400 (200–1000) |
| FEV1 L | 2.68±0.85 |
| FEV1 % predicted | 89.85±19.15 |
| FVC L | 3.65±1.00 |
| FVC % predicted | 99.81±16.87 |
| Airway hyperresponsiveness PC20 mg·mL−1 geometric mean (95% CI) | 8.02 (6.31–10.17) |
| Blood IgE kIU·L−1 | 91.5 (28.50–253.50) |
| Blood eosinophils ×109 cells·L−1 | 0.20 (0.12–0.32) |
| Sputum eosinophils % | 0.80 (0.25–4.75) |
| Sputum neutrophils % | 64.75 (42.25–84.00) |
| ACQ-5 score | 0.60 (0.20–1.00) |
Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. BTS: British Thoracic Society; BMI: body mass index; BDP: beclomethasone dipropionate; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; PC20: provocative concentration of methacholine producing a 20% fall in FEV1; ACQ-5: five-item Asthma Control Questionnaire. #: n=191; ¶: QVAR (Teva, Castleford, UK), 2:1 BDP; Flixotide (GlaxoSmithKline, London, UK), 2:1 BDP; budesonide, 1:1 BDP.